AboutMesothelioma.Net

Mesothelioma: One of Over 6,000 Orphan Diseases

Friday, March 5, 2010

by Nancy Meredith
In the United States an “orphan disease” status is assigned to a disease or disorder if it affects fewer than 200,000 Americans at any given time. The Food and Drug Administration estimates that today there are over 6,000 rare diseases affecting more than 25 million people. According to the National Organization for Rare Disorders (NORD), 1 out of 10 Americans have a rare disease.

Mesothelioma is an aggressive form of cancer primarily caused by exposure to airborne asbestos fibers that is diagnosed in 3,000 Americans each year. Mesothelioma shares the orphan disease distinction with other well-known diseases including colon cancer, multiple sclerosis, AIDS, and cerebral palsy. Between 85 and 90 percent of the orphan diseases are serious or life-threatening.

1983 Orphan Drug Act
Many of these diseases afflict so few people that researchers and pharmaceutical companies do not find it beneficial to expend the time, effort or money to find treatments and cures. As a result foundations and organizations were formed to fund grants to entice researchers to dedicate resources to “their” disease, or to advocate Congress for support.

NORD was established in 1983 by patients and families who encouraged the U.S. government to take action towards supporting researchers in focusing on rare diseases such as mesothelioma.

In 1983 Congress passed the U.S. Orphan Drug Act offering financial incentives to help companies recover the cost of developing a drug for small patient populations. Orphan drug designation, which is intended to facilitate drug development, provides substantial potential benefits to the sponsor, including funding for certain clinical studies, study-design assistance, and several years of market exclusivity for the product upon regulatory approval.

The Office of Orphan Products
The Office of Orphan Products Development (OOPD), under the direction of the FDA, is dedicated to promoting and advancing the development of products (drugs, biologics, medical devices, and medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

In addition, the office is to provide coordination among Federal, other public, and private agencies in carrying out their respective functions relating to the development of products for rare diseases or disorders.

According to the FY2010 OOPD Budget Report the Orphan Drug Act, and the operation of the program, has been successful. As of April 21, 2009, 339 drugs and biological products for rare diseases have been brought to market. In comparison, only 10 such designated products had been approved in the 10 years prior to the 1983 act.

Orphan Drug Grants
The OOPD also funds the Research Grants Program. The goal of the grant program is to encourage clinical development of products for use in rare diseases or conditions. The FY2010 budget for orphan product grants is $14,315,864.

Orphan product grants successfully fosters and encourages the development of effective medical products for the treatment and cure of rare diseases. The recipients of the grants are able to focus on product development in a compressed time period with a very modest investment. OOPD grant funding is typically offered for up to three years for Phase 1 trials, and up to four years for Phase 2 and 3 trials.

In addition, the Department of Defense awarded several million dollars for three important mesothelioma projects. The funds will support research into early detection of the disease and the development of new treatments, including clinical trials for a promising new vaccine that will directly impact patients.

Orphan Drug Designation
Only one drug has been APPROVED as an orphan drug in the treatment of mesothelioma. Pemetrexed Disodium (Alimta) was designated on February 28, 2001, with an exclusivity start date of February 4, 2004, for the treatment of malignant pleural mesothelioma. Specifically the approved orphan indication is for treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery.

The following drugs hold the Orphan Drug designation status for the treatment of malignant mesothelioma, but have not yet been approved.

• 5,6-Dihydro-5-Azacytidine from ILEX Oncology, Inc, designated 5-11-1992
• Arenegyr from MolMed S.p.A. (Italian), designated 08-22-2008
• Aroplatin from Antigenics Incorporated, designated 09-01-1999
• Onconase from Alfacell Corporation, designated 01-25-2007
• Ss1(Dsfv)-Pe38 from National Institutes of Health Cancer Therapy Evaluation Program, designated 02-11-2002
• Vorinostat from Merck & Co., Inc., designated 03-17-2004

Coordination with European Medicines Agency (EMA)
On March 1, the U.S. FDA and the EMA announced they will coordinate on orphan drug designations through acceptance of a single annual report from sponsors of orphan drugs and biologic products designated by both the United States and the European Union. Prior to this agreement, drug sponsors had to submit separate reports.

Both agencies, as well as sponsors, will benefit from the single report. The report will contain a full set of data pertaining to an orphan drug including information on the ongoing clinical studies, a description of the investigation plan for the coming year and information on anticipated or current problems.

The single annual report submission to both regulatory agencies is voluntary and will apply only to sponsors who have obtained an orphan designation status for their product from both the FDA and EMA.

© MesotheliomaHelp.Net. All Rights Reserved. Reprinting or republication of this article or any portion of its content is permitted but must include the MesotheliomaHelp.Net link.

Labels: Featured Story

posted by Nancy Meredith at 7:16 AM
Link to this article